Tag: AZEDRA

14Dec 2016 by Ronny Allan 3 Comments

Neuroendocrine Tumours: a spotlight on Pheochromocytomas and Paragangliomas

Awareness, Patient Advocacy, Technical NETs

I spend a lot of time talking about the most common forms of Neuroendocrine Tumours (NETs), but what about the less well-known types? As part of my commitment to all types of NETs, I'd like to shine a light on two less common tumour types known as Pheochromocytomas and Paragangliomas - incidence rate approximately 8 per million per year. They are normally grouped together and the definitions below will confirm why. If you think it's difficult to diagnose a mainstream NET, this particular sub-type is a real challenge. So, let's get definitions out of the way: Pheochromocytomas (Pheo for short) Pheochromocytomas are tumours of the adrenal gland that produce excess adrenaline. They arise from the central portion of the adrenal gland, which is called the adrenal medulla (the remainder of…

I first heard about this drug at ENETS Barcelona 2017 and then again in 2018. It’s now starting to be discussed in USA including at the 2019 ASCO conference. It was known then as Sulfatinib but for reasons unclear to me it was changed later to Surufatinib. It’s a novel, oral angio-immuno kinase inhibitor that selectively […]

Cancer kills but so can fake cures

No matter where you look on social media, there are millions of sites claiming that ‘this’ and ‘that’ can cure cancer. If you analyse some of the things that can apparently ‘cure’ cancer, you will normally find that behind these fantasies, there is someone selling something, a book, a video, a product. I was also […]

Pancreatic Neuroendocrine Tumours – surgical decisions and new research on molecular sub-types

I offer you two subjects in one article but they are overlapping and very related. The piece of research in the 2nd half of the article is very exciting – did you know researchers have found there are two main sub-types of pNETs, one less likely to recur and metastasise than the other? This will […]

Ronny Allan – Living with Neuroendocrine Neoplasms – Thanks a MILLION

I’m totally astonished to have been able to accumulate a million views of my blog around the middle of June 2019. When I first set it up in Apr 2014, it was just to help spread awareness whilst I was walking the 84 miles of Hadrian’s Wall with my wife Chris. I never thought for one […]

Phase 1 clinical trial of single agent PV-10 for the treatment of symptomatic neuroendocrine tumors (NET) metastatic to the liver

An interesting trial from Provectus Biopharmaceuticals Inc. Phase 1 results were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL from May 31-June 4, 2019 In an ogoing Phase 1 clinical trial of single agent PV-10 for the treatment of symptomatic neuroendocrine tumors (NET) metastatic to the liver. […]

New Radiotracer Can Identify Nearly 30 Types of Cancer – SNMMI – 68Ga-FAPI PET/CT

New radiotracer can identify nearly 30 types of cancer (including NETs). Future potential for therapeutic application. This is a different type of radiotracer being currently being used in the approved market for NETs. It’s availability and timeline is not yet known. Date: June 7, 2019 Source: Society of Nuclear Medicine and Molecular Imaging Summary: A […]